AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/article-1G1-89961723/novuspharma-spa-results-bbr.html" title="Facts and information about Novuspharma SpA results of BBR 2778 study show potential.(product testing)(Brief Article)">Novuspharma SpA results of BBR 2778 study show potential.(product testing)(Brief Article)</a>

Close Set up an RSS feed that alerts you when new articles from Pain & Central Nervous System Week are available.

Frequently asked questions about RSS feeds

Novuspharma SpA results of BBR 2778 study show potential.(product testing)(Brief Article)

Pain & Central Nervous System Week

| August 05, 2002 | COPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2002 AUG 5 - (NewsRx.com & NewsRx.net) -- Novuspharma SpA (NOV.MI), a biotechnology company focused on cancer, announced results from a preclinical study with BBR 2778 in a chronic model of multiple sclerosis.

The results were presented by Dr. Guido Cavaletti of the Bicocca University of Milan, together with colleagues and Novuspharma scientists, at the 12th Meeting of the European Neurological Society in Berlin June 22-26, 2002. BBR 2778 is Novuspharma's intercalating agent currently in phase III clinical trials for the treatment of non-Hodgkin lymphoma.

The aim of the preclinical experiments was to examine the effect of BBR 2778 in a chronic, relapsing, experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis by comparing BBR 2778 with mitoxantrone, an anticancer drug approved in U.S. and certain European countries for the treatment of multiple sclerosis.

The data analyzed so far indicate that ...

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


Novuspharma SpA Announces Results of BBR 2778 Study Show Potential in Chronic...: Press release article from: Business Wire June 24, 2002 700+ words
...Neurological Society in Berlin Novuspharma SpA (Nuovo Mercato:NOV...preclinical study with BBR 2778 in a chronic model...22 to 26 June 2002. BBR 2778 is Novuspharma...c.$3bn by 2004. Novuspharma SpA Novuspharma, based...anti-cancer drug, BBR 2778, has recently...


Novuspharma SpA announces plans for Phase I trial of pixantrone (BBR 2778) in...: News wire article from: Asia Africa Intelligence Wire December 2, 2002 700+ words
...Business NewsBase - Press Release) Novuspharma SpA announces plans to begin a Phase I trial of pixantrone (BBR 2778) in patients with multiple sclerosis...year will be excluded from the study. Novuspharma SpA, based in Bresso, Milan, is an emerging...


Novuspharma SpA Announces Plans for Phase I Trial of Pixantrone (BBR 2778) in...: Press release article from: PR Newswire December 2, 2002 700+ words
BRESSO, Italy -- Novuspharma SpA (Nuovo Mercato: NOV.MI), a biopharmaceutical company primarily...today announces plans to begin a phase I trial of pixantrone (BBR 2778) in patients with multiple sclerosis (MS) in early 2003...


NOVUSPHARMA SPA ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 30...: Press release article from: PR Newswire November 13, 2001 700+ words
...transmitted on behalf of Novuspharma SpA. Co-founders and managers...agreement Bresso, Italy - Novuspharma SpA (Nuovo Mercato: NOV...2004. Highlights: * BBR 2778 commenced recruitment...to begin by year end * BBR 2778 European Phase II...


Novuspharma SpA Announces Financial Results for the Third Quarter Ended 30...: Press release article from: PR Newswire November 13, 2001 700+ words
...Nov. 13 /PRNewswire/ -- Novuspharma SpA (Nuovo Mercato: NOV.MI...November 2004. Highlights: * BBR 2778 commenced recruitment for...expected to begin by year end * BBR 2778 European Phase II trial...at DHGO meeting in Mannheim * BBR 3438/3576 commenced recruitment...


Novuspharma SpA Announces Financial Results for the Three Months Ended 31 March...: Press release article from: PR Newswire May 14, 2003 700+ words
Novuspharma SpA (Nuovo Mercato...for pixantrone (BBR 2778) in indolent...phase II study for BBR 3576 in patients...phase II study for BBR 3576 in prostate...CONTACT: Karl Hanks of Novuspharma SpA, +39-02-61035807...


Novuspharma SpA. (Other News To Note).(Brief Article): Newspaper article from: BioWorld International June 4, 2003 700+ words
* Novuspharma SpA, of Milan, Italy, is planning a second Phase II trial of BBR 3576, its candidate treatment...levels remained unchanged. BBR 3576 is one of two intercalating...developing. A second, pixantrone (BBR 2778), is currently undergoing...


Novuspharma SpA Financial Results for the Ninth Months Ended 30 September 2003.: Press release article from: PR Newswire October 20, 2003 700+ words
Novuspharma SpA (Nuovo Mercato: NOV.MI, NOV IM...US regulatory strategy for Pixantrone (BBR 2778) in relapsed aggressive non-Hodgkin...results of a Phase II study for Pixantrone (BBR 2778) in relapsed aggressive non-Hodgkin...


Novuspharma SpA. (Other News To Note).: Newspaper article from: BioWorld International December 4, 2002 700+ words
Novuspharma SpA, of Bresso, Italy, said it is planning to initiate a Phase I trial of pixantrone (BBR 2778) in patients with multiple sclerosis early next year. The compound, already in Phase III studies for the treatment of non...


Novuspharma SpA Annual General Meeting Statement.: Press release article from: PR Newswire April 24, 2003 700+ words
Novuspharma SpA (Nuovo Mercato: NOV.MI), a...novuspharma.com/. Notes to Editors Novuspharma SpA, based in Bresso, Milan, is a...com/. CONTACT: Karl Hanks of Novuspharma SpA, +39-02-61035807, Mobile...

For more facts and information, see all results

Source: HighBeam Research, Novuspharma SpA results of BBR 2778 study show potential.(product...